Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
复制标题
DOI：
10.1007/s00262-016-1797-6
复制
发表时间：
2016-03
影响因子：
5.8
通讯作者：
Paulos, Chrystal M.
中科院分区：
文献类型：
--
作者：
Majchrzak, Kinga;Nelson, Michelle H.;Bailey, Stefanie R.;Bowers, Jacob S.;Yu, Xue-Zhong;Rubinstein, Mark P.;Himes, Richard A.;Paulos, Chrystal M.
癌症免疫疗法是治疗肿瘤患者最有效的方法之一，因为它支持记忆T细胞的产生和持久性。在临床前工作中，据报道过继转移的分泌IL-17 A的CD 4+和CD 8+淋巴细胞（即，Th 17和Tc 17细胞）在体内比IFN-γ+ Th 1或Tc 1细胞更大程度地使肿瘤消退。在此，我们回顾的机制如何输注的Th 17和Tc 17细胞消退建立恶性肿瘤在临床相关的小鼠模型的癌症。我们还讨论了独特的信号线索，如共刺激分子（ICOS和41 BB），细胞因子（IL-12和IL-23）或药物试剂（Akt抑制剂等），可用于增强IL-17+淋巴细胞的治疗潜力，重点是利用这些知识来改善癌症患者的下一代临床试验。
Cancer immunotherapy is one the most effective approaches for treating patients with tumors, as it bolsters the generation and persistence of memory T cells. In preclinical work, it has been reported that adoptively transferred CD4+ and CD8+ lymphocytes that secrete IL-17A (i.e., Th17 and Tc17 cells) regress tumors to a greater extent than IFN-γ+Th1 or Tc1 cells in vivo. Herein, we review the mechanisms underlying how infused Th17 and Tc17 cells regress established malignancies in clinically relevant mouse models of cancer. We also discuss how unique signaling cues—such as co-stimulatory molecules (ICOS and 41BB), cytokines (IL-12 and IL-23) or pharmaceutical reagents (Akt inhibitors, etc.)—can be exploited to bolster the therapeutic potential of IL-17+ lymphocytes with an emphasis on using this knowledge to improve next-generation clinical trials for patients with cancer.
登录
查看更多内容
人白细胞介素17产生的细胞起源于CD161+ CD4+ T细胞前体。
影响因子：
15.3
作者：
Cosmi, Lorenzo;De Palma, Raffaele;Santarlasci, Veronica;Maggi, Laura;Capone, Manuela;Frosali, Francesca;Rodolico, Gabriella;Querci, Valentina;Abbate, Gianfranco;Angeli, Roberta;Berrino, Liberato;Fambrini, Massimiliano;Caproni, Marzia;Tonelli, Francesco;Lazzeri, Elena;Parronchi, Paola;Liotta, Francesco;Maggi, Enrico;Romagnani, Sergio;Annunziato, Francesco
通讯作者：
Annunziato, Francesco
影响因子：
82.9
作者：
Gattinoni L;Lugli E;Ji Y;Pos Z;Paulos CM;Quigley MF;Almeida JR;Gostick E;Yu Z;Carpenito C;Wang E;Douek DC;Price DA;June CH;Marincola FM;Roederer M;Restifo NP
通讯作者：
Restifo NP
影响因子：
32.4
作者：
Chalmin, Fanny;Mignot, Gregoire;Ghiringhelli, Francois
通讯作者：
Ghiringhelli, Francois
影响因子：
44.1
作者：
Chang, Seon Hee;Dong, Chen
通讯作者：
Dong, Chen
影响因子：
4.4
作者：
Bengsch, Bertram;Seigel, Bianca;Thimme, Robert
通讯作者：
Thimme, Robert